secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akari Therapeutics Plc (AKTX)
CIK:        0001541157
Form:       8-K
Filed at:   2025-04-16T23:59:59+00:00
Accession:  0000950170-25-054484
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akari Therapeutics FY2024 net loss $21.6M; cash runway into Sep 2025; new CEO named
--------------------------------------------------------------------------------

- FY2024 net loss from operations $21.6M vs $16.8M in 2023; R&D $7.0M, G&A $9.7M.
- Cash $2.6M at Dec 31, 2024; plus $6.6M private placement in March 2025 funds operations into Sep 2025.
- Lead ADC AKTX-101 (TROP2 PH1) for solid tumors; seeking licensing/strategic partner.
- Abizer Gaslightwala named President and CEO effective April 21, 2025.
- Merger with Peak Bio completed Nov 2024; pipeline focused on next-gen bifunctional ADCs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1541157/000095017025054484/0000950170-25-054484-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1541157/000095017025054484/aktx-20250416.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-054484

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer